78 Bibliografia [1] Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chron Dis. 1970;23: 455-468 [2] Extermann M. Measurement and impact of comorbidity in oldercancerpatients. CritRevOncolHematol. 2000;35: 181-200. [3] Brunner AM, Kim HT, Coughlin E, et al. Outcomes in Patients Age 70 or Older Undergoing Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies. Biol Blood Marrow Transplant. 2013. 19:1374-1380 [4]McClune BL, Weisdorf DJ, Pedersen TL, et al. J ClinOncol. 2010 Apr 10;28(11):1878-87 [5]Sorror ML, Storb RF, Sandmaier BM, et al. Comorbidity-Age Index: A Clinical Measure of Biologic Age BeforeAllogeneicHematopoietic Cell Transplantation. J ClinOncol . 2014 Oct 10;32(29):3249-56 [6] Scott BL, Pasquini MC, Logan BR, et al. Myeloablative Versus Reduced-IntensityHematopoietic Cell Transplantation for Acute MyeloidLeukemia and MyelodysplasticSyndromes. J ClinOncol . 2017 Apr 10;35(11):1154-1161 [7] Piemontese S, Lazzari L, Ruggeri A, et al. Allogeneichematopoieticstemcelltransplantation in patientsolderthan 65 years with acute myeloidleukemia and myelodysplasticsyndrome: a 15year experience. Bone MarrowTransplant . 2022 Apr;57(4):678680 [8]Sorror ML, Maris MB, Storb R, et al. Hematopoieticcelltransplantation (HCT)-specificcomorbidityindex: a new tool for risk assessmentbeforeallogeneic HCT. Blood. 2005;106:2912–9 [9] Raimondi R, Tosetto A, Oneto R, et al. Validation of the Hematopoietic Cell Transplantation-SpecificComorbidity Index: a prospective, multicenter GITMO study. Blood. 2012;120:1327–33 [10]Parimon T, Au DH, Martin PJ, Chien JW. A risk score for mortalityafterallogeneichematopoieticcelltransplantation. AnnInternMed. 2006;144:407–14 [11]Hemmati PG, Terwey TH, le Coutre P, et al. A modified EBMT risk score predicts the outcome of patients with acute myeloidleukemiareceivingallogeneicstemcelltransplants. Eur J Haematol. 2011;86:305–16 [12] Armand P, Kim HT, Logan BR, et al. Validation and refinement of the Disease Risk Index for allogeneicstemcelltransplantation. Blood. 2014;123:3664–71 [13] Shouval R, Fein JA, Cho C, et al. The SimplifiedComorbidity Index: a new tool for prediction of nonrelapsemortality in allo-HCT. Blood Adv. 2022;6:1525–35
RkJQdWJsaXNoZXIy ODUzNzk5